Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14778MR)

This product GTTS-WQ14778MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12843MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ12713MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ1282MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ12120MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ283MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ8183MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ3974MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ5213MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW